Objective

2

To

observe the efficacy of

Shugan Zhixuan

Decoction

in treating residual dizziness （liver depression and spleen deficiency syndrome） after reposition in patients with primary posterior semicircular canal benign paroxysmal positional vertigo （BPPV）.

Methods

2

A total of 80 patients with primary posterior semicircular canal BPPV and residual dizziness （liver depression and spleen deficiency syndrome） who were diagnosed at the Vestibular Center， Department of Otorhinolaryngology， Dongfang Hospital， Beijing University of Chinese Medicine from June 2022 to March 2023 were selected. These patients were randomly divided into the observation group and the control group using a random number table. The observation group received

Shugan Zhixuan

Decoction

granules， while the control group received a placebo simulating

Shugan Zhixuan

Decoction

. Both groups were administered 1 packet per dose， twice a day， dissolved in 50–100 mL of warm water， for 14 consecutive days. Before and after treatment， the traditional Chinese medicine （TCM） dizziness syndrome scale score and therapeutic effect were compared between the two groups. Additionally， the Modified Clinical Test of Sensory Interaction on Balance （mCTSIB） was used to measure static postural sway under four conditions ［eyes open on firm surface （Firm-EO）， eyes closed on firm surface （Firm-EC）， eyes open on foam surface （Foam-EO）， and eyes closed on foam surface （Foam-EC）］. The swaying velocity was compared. The Dizziness Handicap Inventory （DHI） scores were also compared.

Results

2

After treatment， both groups showed a significant decrease in TCM dizziness syndrome scale scores compared to baseline （

P

<

0.05）. The observation group had lower TCM dizziness syndrome scale scores than the control group （

P

<

0.05）. The total effective rate in the observation group was 91.67%， significantly

higher than 73.68% in the control group （

P

<

0.05）. After treatment， the sway velocity under Foam-EO and Foam-EC conditions decreased in both groups compared to baseline （

P

<

0.05）， with the observation group showing a lower sway velocity than the control group （

P

<

0.05）. The DHI scores for both groups decreased significantly after treatment （

P

<

0.05）， with the observation group having lower DHI scores than the control group （

P

<

0.05）.

Conclusion

2

Shugan Zhixuan

Decoction

can effectively improve residual dizziness symptoms after reposition in primary posterior semicircular canal BPPV， with significant therapeutic efficacy.